A database of FDA approved therapeutic peptides and proteins
| ID | ThPPID | Name | Peptide Sequence | Length | Functional Classification | Disease | Brand | Company | Physical Appearance | Route of Administartion | Category | Target |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1205 | Th1027 | Insulin Regular | A-chain:GIVEQCCTSIC< Full view | 51 | Ia | Genetic/Hormonal | Humulin R | Eli Lilly and Company | Sterile, clear, aqueous, and colorless solution | Subcutaneous injection in the abdominal wall, the thigh, the gluteal region or in the upper arm and Intravenousadministration of Humulin R (insulin (human recombinant)) U-100 is possible under medical supervision. | Antidiabetic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
| 1206 | Th1027 | Insulin Regular | A-chain:GIVEQCCTSIC< Full view | 51 | Ia | Genetic/Hormonal | Novolin R | Novo Nordisk | Sterile, clear, aqueous, and colorless solution | Subcutaneous and Intravenous infusion | Antidiabetic Agents | Insulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
| 1252 | Th1035 | Glucagon recombinant | HSQGTFTSDYSKYLDSRRAQ Full view | 29 | IV | Hormonal/Metabolic/genetic | GlucaGen | Novo Nordisk | Sterile, lyophilized white powder | Subcutaneous, Intramuscular, or Intravenous infusion | Hypoglycemic Agents | Glucagon receptor,Glucagon-like peptide 2 receptor,Glucagon-like peptide 1 receptor |
| 1253 | Th1035 | Glucagon recombinant | HSQGTFTSDYSKYLDSRRAQ Full view | 29 | IV | Hormonal/Metabolic/genetic | Glucagon | Eli Lilly | Powder | Subcutaneously or Intramuscularly Injection | Hypoglycemic Agents | Glucagon receptor,Glucagon-like peptide 2 receptor,Glucagon-like peptide 1 receptor |
| 1275 | Th1040 | Insulin Lispro | A chain:GIVEQCCTSICS Full view | 51 | Ia | Hormonal/Metabolic/genetic | Humalog | Eli Lilly | Sterile, aqueous, clear, and colorless solution | Subcutaneous and Intravenous infusion | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
| 1276 | Th1040 | Insulin Lispro | A chain:GIVEQCCTSICS Full view | 51 | Ia | Hormonal/Metabolic/genetic | Humalog KwikPen | Eli Lilly | Solution | Subcutaneous injection | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
| 1277 | Th1040 | Insulin Lispro | A chain:GIVEQCCTSICS Full view | 51 | Ia | Hormonal/Metabolic/genetic | Humalog Pen | Eli Lilly | N.A. | N.A. | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
| 1283 | Th1041 | Insulin Glargine | A-chain:GIVEQCCTSICS Full view | 53 | Ia | Hormonal/Metabolic/genetic | Lantus | Sanofi-Aventis | Solution | Subcutaneous injection | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
| 1284 | Th1041 | Insulin Glargine | A-chain:GIVEQCCTSICS Full view | 53 | Ia | Hormonal/Metabolic/genetic | Lantus OptiSet | N.A. | Solution | Subcutaneous injection | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
| 1285 | Th1041 | Insulin Glargine | A-chain:GIVEQCCTSICS Full view | 53 | Ia | Hormonal/Metabolic/genetic | Lantus SoloStar | N.A. | Solution | Subcutaneous injection | Hypoglycemic Agents, Antidiabetic agents | Insulin receptor,Insulin-like growth factor 1 receptor |
| 1305 | Th1043 | Rasburicase | SAVKAARYGKDNVRVYKVHK Full view | 255 | Ic | Metabolic/Genetic | Elitek | Sanofi-Synthelabo Inc | Sterile, white to off-white, lyophilized powder | Intravenous administration | Antihyperuricemic Agents, Gout suppressants | Uric acid |
| 1306 | Th1043 | Rasburicase | SAVKAARYGKDNVRVYKVHK Full view | 255 | Ic | Metabolic/Genetic | Fasturtec | N.A. | Powder and solvent that are made upto make solution. | Intravenous administartion | Antihyperuricemic Agents, Gout suppressants | Uric acid |
| 1327 | Th1046 | Abciximab | H ReoPro-like antibo Full view | 218 | IIa | Genetic/Metabolic/Haemetological | ReoPro | Eli Lilly and Company | Clear, colorless, sterile, non-pyrogenic solution | Intravenous administartion | Platelet Aggregation Inhibitors, Anticoagulants | Integrin beta-3,Integrin alpha-IIb,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immuno |
| 1361 | Th1051 | Human Serum Albumin | MKWVTFISLLFLFSSAYSRG Full view | 609 | Ia | Hematological/Metabolic/genetic | Albuminar | CSL Behring | Sterile aqueous solution of albumin obtained from large pools of adult human venous plasma by low temperature controlled fractionation according to the Cohn process. | Albumin (Human) 25%, Albuminar-25 (albumin human) , is to be administered by the Intravenous route. | Serum substitutes | N.A. |
| 1362 | Th1051 | Human Serum Albumin | MKWVTFISLLFLFSSAYSRG Full view | 609 | Ia | Hematological/Metabolic/genetic | Albutein | GRIFOLS | Sterile, aqueous solution for single dose intravenous administration containing 20% human albumin (weight/volume). | Albutein 20% is to be administered by the Intravenous route. | Serum substitutes | N.A. |
| 1422 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | Pancrecarb | Digestive care US, Inc. | Delayed-Release Capsules, Buffered and Enteric-Coated Microspheres. | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1423 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | Viokace | Aptalis Pharma US, Inc. | Beige-white amorphous powder, miscible in water and practically insoluble in alcohol and converted to tablet form | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1424 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | ULTRESA | Aptalis Pharma US, Inc. | Beige-white amorphous powder, miscible in water and practically insoluble or insoluble in alcohol and ether and converted to Delayed-Release Capsules | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1425 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | PERTZYE | Digestive care US, Inc. | Beige-white amorphous powder, miscible in water and practically insoluble or insoluble in alcohol and ether PERTZYE delayed-release capsule | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1426 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | ULTRASE | Axcan Pharma | Capsules Enteric-Coated Microspheres | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1427 | Th1071 | Pancrelipase | Pancreatic alpha amy Full view | 1206 | Ia | Metabolic/genetic/ | ZENPEP | Aptalis Pharma US, Inc. | Delayed-Release Capsules | Oral route | Gastrointestinal Agents and Enzyme Replacement Agents | Synaptosomal-associated protein 25,Rho-related GTP-binding protein RhoB, Dietary fat,Dietary protein,Dietary starch |
| 1445 | Th1079 | Serum Albumin | DAHKSEVAHRFKDLGEENFK Full view | 585 | IV | Metabolic/genetic | Albunex | Mallinckrodt; Tyco Healthcare | N.A. | Intravenous infusion | Serum substitutes | N.A. |
| 1446 | Th1079 | Serum Albumin | DAHKSEVAHRFKDLGEENFK Full view | 585 | IV | Metabolic/genetic | Optison | GE Healthcare | N.A. | Intravenous infusion | Serum substitutes | N.A. |
| 1453 | Th1083 | Coagulation Factor Ix | YNSGKLEEFVQGNLERECME Full view | 415 | Ia | Hematological/Metabolic/genetic | Alprolix | Biogen Idec Inc., and Genentech USA, Inc | Sterile, non-pyrogenic, preservative-free, white to off-white, lyophilized powder to cake for reconstitution with the provided diluent | Intravenous infusion | Coagulants and Thrombotic Agents | N.A. |
| 1549 | Th1118 | Sulodexide | N.A. Full view | 0 | IIIc | Hormonal/genetic/Hematological/N.A. | SULODEXIDE | Syntex S.A | N.A. | N.A. | Antithrombins and Fibrinolytic Agents and Hypoglycemic Agents and Anticoagulants and Hypolipidemic Agents | Heparin cofactor 2,Antithrombin-III |
| 1641 | Th1146 | Lucinactant | KLLLLKLLLLKLLLLKLLLL Full view | 21 | Ib | Genetic | Surfaxin | Discovery Laboratories, Inc. | Suspension | Intratracheal administration | Pulmonary surfactants | N.A. |
| 1644 | Th1147 | Natalizumab | N.A. Full view | 0 | IIa | Genetic/Immunological | Tysabri | Biogen Idec Inc. | Sterile, colorless, and clear to slightly opalescent concentrate | Intravenous infusion | Immunosuppressive agents | N.A. |
| 1694 | Th1166 | Asfotase Alfa | LVPEKEKDPKYWRDQAQETL Full view | 726 | Ia | Genetic Disorders | Strensiq | Alexion Pharma Ghbh | Solution | Subcutaneous | Enzymes Alimentary Tract and Metabolism | Sphingosine 1-phosphate receptor 1; Pyrophosphate |
| 1695 | Th1166 | Asfotase Alfa | LVPEKEKDPKYWRDQAQETL Full view | 726 | Ia | Genetic Disorders | Strensiq | Alexion Pharmaceuticals Inc. | Solution | Subcutaneous | Enzymes Alimentary Tract and Metabolism | Sphingosine 1-phosphate receptor 1; Pyrophosphate |
| 1708 | Th1170 | Blinatumomab | DIQLTQSPASLAVSLGQRAT Full view | 504 | IIIc | Cancer/Genetic | Blincyto | AMGEN | Lyophilized Powder for intravenous administration | Intravenous | Antineoplastic Agents, Immunosuppressive Agents, Monoclonal antibodies, Antineoplastic and Immunomodulating Agents | B-lymphocyte antigen CD19; T-cell surface glycoprotein CD3 delta chain |
| 1715 | Th1171 | C1 Esterase Inhibitor (Human) | NA Full view | 0 | Ia | Genetic Disorders | Berinert 1500 | Csl Behring Canada Inc | kit; Powder for Solution | Intravenous | NA | Plasma protease C1 inhibitor |
| 1717 | Th1171 | C1 Esterase Inhibitor (Human) | NA Full view | 0 | Ia | Genetic Disorders | Cinryze | Viropharma Biologics Inc | Powder for Solution | Intravenous | NA | Plasma protease C1 inhibitor |
| 1722 | Th1173 | Conestat alfa | NA Full view | 0 | Ia | Genetic Disorders | Ruconest | Pharming; Santarus, Inc. | Powder for Solution | Intravenous | NA | NA |
| 1741 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | NA | NA | Injection, Solution; Injection | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 9 |
| 1742 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 10 |
| 1743 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Canada Inc | Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 11 |
| 1744 | Th1179 | Evolocumab | NA Full view | 0 | IIa | Genetic/Metabolic/Cardiac | Repatha | Amgen Inc | Injection, Solution | Subcutaneous | Lipid Modifying Agents, Plain; Cardiovascular System | Proprotein convertase subtilisin/kexin type 12 |
| 1745 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Riastap | Csl Behring Gmb H | Injection, Powder, Lyophilized, for Solution | Intravenous | NA | NA |
| 1746 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Artiss Frozen | Baxter Healthcare Corporation | NA | NA | NA | NA |
| 1747 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Evicel Fibrin Sealant (human) | Ethicon Inc | NA | NA | NA | NA |
| 1748 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Raplixa | Pro Fibrix Bv | NA | NA | NA | NA |
| 1749 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Tachosil | Baxter Healthcare Corporation | NA | NA | NA | NA |
| 1750 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Tisseel | Baxter Healthcare Corporation | NA | NA | NA | NA |
| 1751 | Th1180 | Fibrinogen Concentrate (Human) | NA Full view | 0 | Ia | Genetic/Hematological | Tisseel Frozen | Baxter Healthcare Corporation | NA | NA | NA | NA |
| 1803 | Th1197 | Sebelipase alfa | SGGKLTAVDPETNMNVSEII Full view | 378 | Ia | Genetic Disorders | Kanuma | Alexion Pharmaceuticals, Inc. | Aqueous Solution | Intravenous infusion | Enzymes | NA |
| 1804 | Th1198 | Sacrosidase | NA Full view | 0 | Ia | Genetic Disorders | Sucraid | QOL Medical, LLC | Solution | Oral | Enzymes | NA |